3DM Inc. Adds Leading Cardiology and Orthopedic Clinicians to Clinical Advisory Board

Expertise in Regenerative Medicine, Interventional Cardiology and Orthopedic Surgery

Cambridge , Mass. – 19 September, 2006 – 3DM Inc. is pleased to announce the addition of two distinguished clinicians from Harvard University's Schools of Medicine and Dental Medicine.

"Drs. Julie Glowacki and Jeffrey Popma bring a wealth of surgical and clinical expertise to two of 3DM's focused efforts in orthopedic and cardiac tissue regeneration," said Zen Chu, 3DM's President. "3DM will benefit immensely from their experience as we prepare for human clinical studies and navigate 3DM's clinical and regulatory paths."

Julie Glowacki, Ph.D., Professor, Harvard Medical School
Dr. Glowacki is a Professor in the Department of Orthopedic Surgery, School of Medicine, and a Professor in the Department of Oral/Maxillofacial Surgery at the School of Dental Medicine at Harvard University. The author of over 100 articles and multiple textbooks and book chapters, Dr. Glowacki’s research examines bone regeneration, the function of engineered joints, the molecular mechanisms by which demineralized bone initiates cartilage formation, and the mechanisms by which steroids (androgens) increase bone mass in young patients with accelerated bone loss due to anorexia nervosa. Dr. Glowacki has served as an independent member of numerous FDA review boards for bone and dental implants and factors for bone regeneration.

Jeffrey Popma, M.D., Associate Professor, Harvard Medical School
Dr. Jeffrey Popma is Director of the Angiographic Core Laboratory at the Brigham and Women’s Hospital, Director of Interventional Cardiology at the Brigham and Women’s Hospital and Associate Professor of Medicine at Harvard Medical School. Dr. Popma has authored more than 200 articles on new device intervention. In his research, he has developed innovative analysis methods for atherectomy, thrombectomy, stenting, chronic total occlusion, drug-eluting stents, and he has improved techniques for assessing the results of photoangioplasty and distal coronary protection devices. He also has expertise in the analysis of carotid stenting, and is the principal Angiographic Core Laboratory investigator on 4 carotid stenting trials.

Recent Independent Publications:

Cardiac Regeneration: Hsieh PC, Davis ME, Gannon J, MacGillivray C, Lee RT. Controlled delivery of PDGF-BB for myocardial protection using injectable self-assembling peptide nanofibers. J Clin Invest. 116(1):237-48 (2006).

Angiogenesis & Cardiac Tissue Engineering: Narmoneva, D., Oni, O., Sieminski, AL, Zhang, S., Gertler, JP, Kamm, RD, Lee, RT Self-assembling short oligopeptides and the promotion of Angiogenesis. Biomaterials 26: 4837–4846 (2005).

Stem Cells for Cartilage Tissue Engineering: Mauck RL, Helm JM, Tuan RS.  Enhanced Chondrogenesis and Development of Mechanical Properties of Human Mesenchymal Stem Cells Seeded in a Self-Assembling Peptide Hydrogel.  Summer Bioengineering Conference, Vail, CO. (2005).

About PuraMatrix
PuraMatrix Synthetic Peptide Hydrogels are the best-selling synthetic scaffolds for cell culture and bioproduction research, and have won numerous scientific awards. PuraMatrix gels consist of smart polymers, self-assembling upon injection in vivo to create biocompatible nanofiber scaffolds and facilitate tissue regeneration. PuraMatrix is currently in pre-clinical testing for orthopedics, cardiac and other medical device and drug delivery applications. PuraMatrix is used by most of the leading pharmaceutical, biotechnology and academic laboratories and has been featured in over thirty premier scientific journal publications. R&D Magazine recently awarded PuraMatrix its 42nd annual R&D 100 Prize as one of the most significant new products to impact life science and medical research.

About 3DM Inc.
3DM is a privately-held specialty biomaterials and medical device company headquartered in Cambridge, Massachusetts, with a mission of developing novel medical therapies through its family of synthetic  nano-scale scaffolds for accelerating wound healing and tissue regeneration. 3DM’s materials provide a critical bridge in wound healing and tissue regeneration –a resorbable injectable scaffold to accelerate ingrowth of normal local tissue.  3DM is developing their self-assembling peptide hydrogels as medical devices in orthopedics, cardiovascular therapies and drug delivery applications. The patented technology, exclusively licensed from Massachusetts Institute of Technology, was pioneered at MIT through the work and expertise of Drs. Shuguang Zhang, Alan Grodzinsky, Robert Langer, Alexander Rich, Carlos Semino and Lisa Spirio.

Source: 3DM Inc.
               puramatrix.com

Contact: Zen Chu , President
                877-430-9595 contact@puramatrix.com